These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 9126900)

  • 1. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
    J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea for treatment of unresectable meningiomas.
    Schrell UM; Rittig MG; Koch U; Marschalek R; Anders M
    Lancet; 1996 Sep; 348(9031):888-9. PubMed ID: 8826822
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of unresectable skull base meningiomas with somatostatin analogs.
    Schulz C; Mathieu R; Kunz U; Mauer UM
    Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.
    Newton HB; Scott SR; Volpi C
    Br J Neurosurg; 2004 Oct; 18(5):495-9. PubMed ID: 15799152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Mazza E; Brandes A; Zanon S; Eoli M; Lombardi G; Faedi M; Franceschi E; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):115-20. PubMed ID: 26659583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea chemotherapy in the treatment of meningiomas.
    Newton HB
    Neurosurg Focus; 2007; 23(4):E11. PubMed ID: 17961035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of high risk or recurrent meningiomas with hydroxyurea.
    Rosenthal MA; Ashley DL; Cher L
    J Clin Neurosci; 2002 Mar; 9(2):156-8. PubMed ID: 11922703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
    Chamberlain MC; Glantz MJ
    Cancer; 2008 Oct; 113(8):2146-51. PubMed ID: 18756531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea chemotherapy for unresectable or residual meningioma.
    Newton HB; Slivka MA; Stevens C
    J Neurooncol; 2000 Sep; 49(2):165-70. PubMed ID: 11206012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
    Ragel BT; Gillespie DL; Kushnir V; Polevaya N; Kelly D; Jensen RL
    Neurosurgery; 2006 Nov; 59(5):1109-20; discussion 1120-1. PubMed ID: 17143245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-resectable slow-growing meningiomas treated by hydroxyurea.
    Loven D; Hardoff R; Sever ZB; Steinmetz AP; Gornish M; Rappaport ZH; Fenig E; Ram Z; Sulkes A
    J Neurooncol; 2004; 67(1-2):221-6. PubMed ID: 15072471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal meningioma during hydroxyurea therapy. A paradoxycal case report.
    Giordano F; Savarino A; Pagni CA
    Neurol Sci; 2002 Sep; 23(3):127-9. PubMed ID: 12391498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas : long-term experience and review of the literature.
    Milker-Zabel S; Zabel-du Bois A; Huber P; Schlegel W; Debus J
    Strahlenther Onkol; 2006 Nov; 182(11):635-40. PubMed ID: 17072520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. En plaque sphenoid wing meningiomas: recurrence factors and surgical strategy in a series of 71 patients.
    Mirone G; Chibbaro S; Schiabello L; Tola S; George B
    Neurosurgery; 2009 Dec; 65(6 Suppl):100-8; discussion 108-9. PubMed ID: 19934984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hydroxyurea treatment for unresectable meningioma].
    Fuentes S; Chinot O; Dufour H; Paz-Paredes A; Métellus P; Barrie-Attarian M; Grisoli F
    Neurochirurgie; 2004 Sep; 50(4):461-7. PubMed ID: 15547484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of meningiomas.
    Alexiou GA; Gogou P; Markoula S; Kyritsis AP
    Clin Neurol Neurosurg; 2010 Apr; 112(3):177-82. PubMed ID: 20056312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
    Hahn BM; Schrell UM; Sauer R; Fahlbusch R; Ganslandt O; Grabenbauer GG
    J Neurooncol; 2005 Sep; 74(2):157-65. PubMed ID: 16193387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiation treatment for recurrent nonbenign meningiomas.
    Mattozo CA; De Salles AA; Klement IA; Gorgulho A; McArthur D; Ford JM; Agazaryan N; Kelly DF; Selch MT
    J Neurosurg; 2007 May; 106(5):846-54. PubMed ID: 17542529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.